pituitary diseases

An Expression of Concern has been posted regarding work in somatotroph adenomas that linked CDKN2A (p16INK4A) to CDK inhibitors response. Because p16INK4A modulates cell cycle control, any claim that it alters anti-tumor activity is clinically relevant. The...

An expression of concern has been issued regarding CDKN2A and response to CDK inhibitors in somatotroph pituitary adenomas, raising uncertainty about a proposed biomarker mechanism. The key signal is that p16INK4A status may not yet reliably predict drug ef...